ANIK
Anika Therapeutics, Inc. Healthcare - Drug Manufacturers - Specialty & Generic Investor Relations →
Anika Therapeutics, Inc. (ANIK) closed at $13.85 as of 2026-03-20, trading 32.1% below its 200-week moving average of $20.38. This places ANIK in the extreme value zone. The stock is currently moving closer to the line, down from -30.5% last week. With a 14-week RSI of 81, ANIK is in overbought territory.
Trading volume is running at 1.1x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.32 ratio) is neutral — neither side is clearly dominating.
Over the past 1667 weeks of data, ANIK has crossed below its 200-week moving average 16 times. On average, these episodes lasted 52 weeks. The average one-year return after crossing below was -15.4%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $200 million, ANIK is a small-cap stock. The company generates a free cash flow yield of 6.7%, which is healthy. Return on equity stands at -6.7%. The stock trades at 1.3x book value.
Management has been repurchasing shares, with a 5.0% reduction over three years. This stock also meets the Yartseva multibagger criteria as a small-cap with strong free cash flow yield and reasonable book value.
Over the past 32 years, a hypothetical investment of $100 in ANIK would have grown to $554, compared to $2535 for the S&P 500. ANIK has returned 5.5% annualized vs 10.6% for the index, underperforming the broader market over this period.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: ANIK vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After ANIK Crosses Below the Line?
Across 16 historical episodes, buying ANIK when it crossed below its 200-week moving average produced an average return of -14.1% after 12 months (median -17.0%), compared to +3.7% for the S&P 500 over the same periods. 38% of those episodes were profitable after one year. After 24 months, the average return was -8.6% vs +13.8% for the index.
Each line shows $100 invested at the moment ANIK crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
ANIK has crossed below its 200-week MA 16 times with an average 1-year return of +-15.4% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Apr 1994 | Apr 1995 | 51 | 47.6% | N/A | +403.6% |
| Apr 1995 | Jul 1995 | 12 | 14.4% | +62.5% | +454.0% |
| Aug 1995 | Sep 1995 | 1 | 2.9% | +88.1% | +427.6% |
| Oct 1998 | Jun 1999 | 35 | 29.3% | +16.7% | +163.8% |
| Aug 1999 | Aug 1999 | 2 | 2.1% | -76.9% | +109.1% |
| Sep 1999 | Jan 2000 | 20 | 19.5% | -74.2% | +128.5% |
| Apr 2000 | Apr 2000 | 2 | 4.5% | -86.0% | +97.9% |
| May 2000 | May 2003 | 154 | 88.7% | -35.0% | +571.5% |
| Jan 2008 | Jan 2011 | 159 | 74.1% | -59.3% | +25.7% |
| Apr 2011 | Oct 2011 | 27 | 24.0% | +103.4% | +66.9% |
| Apr 2018 | Jul 2019 | 65 | 33.3% | -24.6% | -68.5% |
| Jan 2020 | May 2021 | 69 | 44.4% | -13.6% | -69.5% |
| Jun 2021 | Jun 2021 | 1 | 6.6% | -44.8% | -65.4% |
| Jul 2021 | Aug 2021 | 5 | 5.4% | -43.0% | -66.0% |
| Aug 2021 | Oct 2021 | 6 | 5.6% | -44.1% | -65.9% |
| Nov 2021 | Ongoing | 228+ | 66.0% | Ongoing | -64.2% |
| Average | 52 | — | +-15.4% | — |
Frequently Asked Questions
Is ANIK below its 200-week moving average?
Yes. As of 2026-03-20, Anika Therapeutics, Inc. (ANIK) is trading 32.1% below its 200-week moving average of $20.38. The current price is $13.85.
What is ANIK's 200-week moving average price?
Anika Therapeutics, Inc.'s 200-week moving average is $20.38 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when ANIK drops below its 200-week moving average?
ANIK has crossed below its 200-week moving average 16 times in our data. The average one-year return after these crossings was -15.4%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 52 weeks on average.
Is ANIK a good value right now?
Here's what our data says about ANIK as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 81 (overbought). Free cash flow yield is 6.7%. Return on equity is -6.7%. Price-to-book is 1.3x. This is not a buy or sell recommendation — always do your own research.
How does ANIK compare to the S&P 500?
Over the past 32 years, $100 invested in ANIK would have grown to $554, compared to $2535 for the S&P 500. That's 5.5% annualized vs 10.6% for the index. ANIK has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20